VRNA Christina Ackermann sells $338K worth of shares
May 17, 2025, 4:35 AM
0.00%
What does VRNA do
Verona Pharma Plc develops therapeutics for respiratory diseases, focusing on its investigational inhaled drug, ensifentrine, for chronic obstructive pulmonary disease (COPD). Two additional formulations of ensifentrine are in Phase II development.
Christina Ackermann sold 40,000 shares of VRNA on 14 May at $8.44 per share, worth a total of $338K. They now own 41,880 VRNA shares, or a 49% holding decrease.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
